A White House panel issued a report Tuesday urging several steps designed to curb rising prices for cancer medications, notably a recommendation for determining value for these increasingly expensive treatments, which can cost $100,000 or more a year.
“The panel concluded that misalignment of drug prices and value is a critical problem that must be addressed,” wrote the three-member panel, an advisory group created under President Nixon in 1971. “Achieving better alignment could improve the quality of cancer care; create incentives for development of innovative, effective new drugs; and help address increases in drug spending that are threatening to put high-value drugs out of reach for some patients.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
